The defect of SFRP2 modulates an influx of extracellular calcium in B lymphocytes
© Tokuda et al.; licensee BioMed Central Ltd. 2014
Received: 16 October 2013
Accepted: 24 October 2014
Published: 4 November 2014
In the Wnt pathway, the secreted frizzled-related protein 2 (SFRP2) is thought to act as one of the several competitive inhibitors of Wnt. However, the precise role of SFRP2 is still poorly understood especially in B lymphocytes. Here, we investigated the function of SFRP2, comparing the SFRP2 defective as well as normal B lymphocytes in mice.
We demonstrated that calcium influx from extracellular to intracellular space in splenic B cells was clearly affected by the defect of SFRP2. In addition, the phosphorylation of phospholipase Cγ2 was observed to be reduced in SFRP2 defective splenic B cells with B cell receptor stimulation.
SFRP2 is suggested to modulate the influx from extracellular calcium in the B cell receptor signaling pathway.
KeywordsSFRP2 PLCγ2 Calcium influx B cell receptor signaling
The Wnt pathway is one of the important signal mechanisms related to cell differentiation in embryogenesis, hematopoiesis, and carcinogenesis . It is mainly divided into three categories as Wnt/β-catenin, Wnt/planar cell polarity, and Wnt/calcium pathway [2–5]. In particular, the Wnt/β-catenin pathway, which also termed as “canonical pathway”, has been investigated extensively and well understood, comparing to other pathways termed as “noncanonical pathway” [6, 7].
The Wnt protein is one of the extracellular ligands binding to the family of Frizzled receptors associated with several receptor-related proteins. Also, the Wnt pathways are regulated with activators or inhibitors . Especially, the secreted frizzled-related protein 2 (SFRP2) (also known as SDF5 ) is a competitive inhibitor to act as antagonist of the Wnt pathway [10, 11].
During embryogenesis, where Wnt signaling is involved, the defect of Sfrp2 causes brachysyndactyly in mice . Our previous research also showed that the dysfunction of SFRP2 protein yields a phenotype of preaxial synpolydactyly and syndactyly . Moreover, SFRP2 has reported to be hypermethylated in the prostate cancer , gastric cancer , and colorectal cancer , and to suppress bone formation in multiple myeloma cells . On the other hand, the Wnt is known to maintain hematopoietic stem cells (HSCs) in the bone marrow (BM) niche under the both canonical  and noncanonical pathways , and various Wnt antagonists such as SFRP2 are suggested to play a role in the regulation of HSCs. In the Wnt pathways of hematopoiesis, SFRP2 as secreted protein is suggested to inhibit the Wnt pathway and maintain the quiescent of HSCs in mice . SFRP2 is also known to be expressed in osteoblasts in BM and related to the proliferation of HSCs . However, the function of SFRP2 on immune system is still unclear, especially in the calcium signaling of B lymphocytes.
Here, we demonstrated that SFRP2 modulates the calcium signal transduction associated with activation cascade in downstream of B cell receptor (BCR) signaling pathway.
Mice of wild-type (Sfrp2 +/+ ) C57BL/6 and of Sfrp2- defective strains (Sfrp2-/-) were bred under the specific pathogen-free (SPF) conditions as described in our previous study . In this study, all mice were examined at 10-12 weeks of age. Reproducibility of data was confirmed by repeating each experiment at least more than three pairs of Sfrp2 +/+ and Sfrp2-/-. All procedures in mouse experiments followed the guidelines and were approved by the Kyoto Prefectural University of Medicine Animal Care and Use Committee.
The cell suspensions were obtained from the BM and spleen samples. After the elimination of red blood cells, the cells in the BM or spleen were suspended in phosphate buffered saline (PBS) with 3% fetal bovine serum. For the western blotting, the splenic B cells were purified by negative isolation using Dynabeads® Mouse CD43 (Untouched™ B Cells) (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol.
Cell differentiation analysis
BM cells were stained by the monoclonal antibodies against the surface markers as follows: FITC-conjugated anti-IgM (II/41), anti-CD43 (S7) and APC-conjugated anti-CD45R/B220 (RA3-6B2; anti-B220). Splenocytes were similarly stained by the monoclonal antibodies as follows: FITC-conjugated anti-CD21/CD35 (7G6), PE-Cy7-conjugated anti-IgM (R6–60.2), anti-B220 antibody (BD Pharmingen, San Diego, CA, USA) and PE-conjugated anti-CD23 (B3B4) antibody (eBioscience, San Diego, CA, USA). All flow cytometry (FACS) experiments were performed by BD FACS Canto II and BD FACSDiva software version 6.1.3 (BD Biosciences, San Jose, CA, USA) according to the manufacturer’s protocol. The analysis was performed using the FlowJo software (Tree Star, San Carlos, CA, USA).
Calcium influx analysis
Cell suspensions of splenocytes were incubated at 37°C for 45 min with Fluo 4-AM (Fluo4; Dojindo, Kumamoto, Japan) and Fura Red™ AM (Fura Red; Invitrogen), which final concentrations were 3 μM and 6 μM, respectively. After stained with anti-B220, the cells were resuspended in calcium-free Hank’s balanced salt solution (HBSS/Ca−). Intracellular calcium levels were assessed by the ratio of the intensities of Fluo4/Fura Red , which the ratios were averaged for every 10 sec. In the experiments, anti-mouse IgM F(ab’)2 fragments (anti-IgM; final concentration 10 μg/ml in HBSS/Ca−, Jackson Immunoresearch, West Grove, PA, USA) and ethylene glycol bis(2-aminoethyl)-N,N,N’,N’-tetraacetic acid (EGTA; final concentration 0.5 mM in HBSS/Ca−), and calcium (Ca; CaCl2 final concentration 1.26 mM in HBSS/Ca−) were applied. These experiments were replicated at least three times.
Endoplasmic reticulum (ER) analysis
The splenocytes were incubated at 37°C in 5% CO2 for 45 min in PBS (Mg+, Ca+) and 1 μM ER-Tracker™ Green dye (glibenclamide BODIPY® FL, ER-Tracker; Molecular Probes, Invitrogen) to evaluate the ER abundance . After staining with anti-B220 for 10 min, the cells were resuspended in PBS (Mg+, Ca+) for FACS analysis.
Reverse Transcription Polymerase Chain Reaction (RT-PCR)
RT-PCR experiments were performed with Multiple Tissue cDNA (MTC) panels of Mouse (Clontech Laboratories, CA, USA) and Sfrp2+/+ and Sfrp2-/- samples, which were from only Sfrp2 +/+ and both mouse for SFRP2 and β-catenin tests, respectively. The cDNAs from Sfrp2+/+ and Sfrp2-/- mouse samples were synthesized in 20 μl products with 200 ng total RNA from splenic B and BM cells and Super Script II (Invitrogen) according to the manufacturer’s protocol. In the PCR process, each cDNA in appropriate mixture was amplified with each specific primer pair, and their details were described in Additional files 1 and 2.
Protein phosphorylation assay by FACS
The phosphorylation assay of proteins was measured by FACS with BD™ Phosflow technology (BD Biosciences) according to the manufacturer’s instructions. The stimulations for splenic B cells were examined by anti-IgM antibody (final concentration 10 μg/ml; Jackson Immunoresearch) or lipopolysaccharide (LPS, final concentration 20 μg/ml; Sigma-Aldrich, San Francisco, CA, USA) in time course of 0, 5, 10, and 15 min. In the case of IgM stimulation, the antibody set of Alexa Fluor® 488 Mouse ERK1/2 (pT202/pY204) (Erk1/2) and PE Mouse anti-Syk (pY348) (Syk) was applied to detect the phosphorylated proteins. In the case of LPS stimulation, Erk1/2 and PE Mouse p38 MAPK (pT180/pY182) (P38) (BD™ Phosflow, BD Biosciences) were examined. These antibodies with anti-B220 were stained for splenic B cells for 30 min in Phosflow experiment process.
The purified splenic B cells were stimulated by anti-IgM (10 μg/ml, Jackson) in HBSS with calcium. The samples were evaluated by antibodies from Antibody Sampler Kits (Cell Signaling Technology, Inc. (CST), Danvers, MA, USA) as follows: anti-phospho-Syk (Tyr525/526), anti-Syk, anti-phospho-Lyn (Tyr507), anti-Lyn, anti-phospho-Btk (Tyr223), anti-Btk, anti-phospho-CD19 (Tyr531), and anti-CD19 from B Cell Signaling Antibody Sampler Kit; anti-phospho-PLCγ2 (Tyr1217), anti-phospho-PLCγ2 (Tyr759), and anti-PLCγ2 antibody from PLCγ Antibody Sampler Kit; anti-phospho-SAPK/JNK (Thr183/Tyr185), and anti-phospho-ATF-2 (Thr71) from Phospho-SAPK/JNK Pathway Antibody Sampler Kit. Moreover, anti-NFAT1, anti-NFAT2, and β-actin antibody (CST) were also applied. These antibodies were detected with anti-rabbit IgG-HRP (CST) as secondary antibody. The signals were detected with the ECL Prime or ECL Plus Western Blotting Detection System (GE Healthcare UK Ltd., Buckinghamshire, UK) according to the manufacturer’s protocol. In addition, the Can Get Signal Immunoreaction Enhancer Solution (Toyobo Co., Ltd, Osaka, Japan) was applied if necessary. The results of western blots were analyzed by ImageJ software (http://imagej.nih.gov/ij/index.html).
In order to prepare the FACS data for statistical analysis, Office Excel and Visual C++ (Microsoft, Redmond, Washington, USA) were used. We employed R software (http://www.R-project.org/) to perform the statistical analysis including t–test in each FACS data and draw the graphs. In the histograms, error bars indicate standard deviation with mean. In addition, the R package of “exactRankTests” was used for Wilcoxon tests.
ER abundance analysis
SFRP2 and β-catenin expression
The expression of SFRP2 studied by RT-PCR was high in BM, but very low in spleen/splenic B cells (Additional file 1). On the other hand, the expression of β-catenin was clearly noted in spleen similar to other tissues, as well as in Sfrp2+/+ and Sfrp2-/- splenocytes (Additional file 2A and B). However, phosphorylated β-catenin was barely detectable in BM or spleen tissues by Western blotting (Additional file 2C).
Western blotting analysis on phosphorylated protein
Before western blots analysis, we first tested each phosphorylation of Erk1/2, P38, and Syk in Sfrp2+/+ and Sfrp2-/- splenic B cells with use of FACS (Additional file 3). Results showed that there was no significant phosphorylation difference between Sfrp2+/+ and Sfrp2-/- when stimulated with either IgM or LPS. Therefore, we examined phosphorylation status of the proteins involved in the BCR signaling pathway with use of western blotting for purified splenic B cells. The purity of splenic B cells was about 98.6% in lymphocytes confirmed by FACS analysis (data not shown).
In addition, NFAT1 and NFAT2 were investigated as downstream components of PLCγ2 in the BCR signaling (Figure 4C). Because there was no difference in these proteins between Sfrp2+/+ and Sfrp2-/-, the defect of Sfrp2 was considered not to play a role in the downstream of PLCγ2. Also, in the downstream of calcium signaling cascade related to BCR signaling pathway, no significant difference of phosphorylation in JNK and ATF-2 was found between Sfrp2+/+ and Sfrp2-/- splenic B cells (Figure 4D).
In this study, we investigated B lymphocytes in mice affected by the defect of Sfrp2, and this defect did not yield the remarkable influence on the early differentiation of B cells (Figure 1). Therefore, we further examined mature B cells in spleen about the influence of the defect of Sfrp2 in intracellular signal transduction in detail.
The calcium signaling plays a very critical role in the immune system including B cells , and so the calcium influx for splenic B cells with Sfrp2 defect was selectively examined. We showed that the calcium signal transduction by BCR activation was slightly increased in Sfrp2+/+ as well as Sfrp2-/- splenic B cells under calcium free condition (open arrows in Figure 2). Moreover, no difference of ER abundance was observed between these B cells (Figure 3). Thus, we could conclude that no significant difference was observed in the intracellular calcium store in both Sfrp2+/+and Sfrp2-/- splenic B cells. However, when the calcium was added in the extracellular space (dotted arrows in Figure 2), intracellular calcium levels were rapidly increased in both Sfrp2+/+ and Sfrp2-/- splenic B cells due to the influx of extracellular calcium by the BCR stimulation. This was considered to be attributed to the activation of calcium release-activated calcium channel in the plasma membrane triggered by emptying of ER calcium stores under calcium free condition and the first IgM stimulation (open arrows in Figure 2) . Subsequently, intracellular calcium levels gradually decreased and differed significantly between Sfrp2+/+ and Sfrp2-/- splenic B cells (Figure 2A). By contrast, intracellular calcium levels were rapidly decreased to the same levels in both splenic B cells after EGTA addition (Figure 2B). Therefore, this phenomenon was observed as a result of the difference of the calcium influx from extracellular to intracellular space between Sfrp2+/+ and Sfrp2-/- splenic B cells.
This calcium influx phenomenon is known to be associated with the activation of several proteins involved in the regulation of cell homeostasis. Specifically, protein tyrosine kinases such as Syk and Lyn are initially activated in response to BCR stimulation, which leads to the activation of Btk and CD19. PLCγ2 is then activated by Btk, and cleaves phosphatidylinositol-bisphosphate (PIP2) into diacylglycerol and inositol (1, 4, 5)-trisphosphate (IP3) by hydrolysis. Subsequently, IP3 induced calcium release from intracellular ER calcium stores by binding to the IP3 receptor. The catalytic hydrolysis of PIP2 is suggested to require the phosphorylation of Tyr759 in PLCγ2 [24, 25]. Moreover, the role of Tyr759 phosphorylation is considered to be different from that of Tyr1217 in PLCγ2 according to the types of cells or stimulations . Our results clearly showed that the defect of Sfrp2 does not affect the phosphorylation of Syk, Lyn, Btk, and CD19, but reduces the phosphorylation of PLCγ2 at Tyr1217, whereas Tyr759 phosphorylation remained unaffected (Figure 4B). This result may indicate that the Sfrp2 participates in not pivotally regulating the catalytic hydrolysis of PIP2 but modulating the calcium signal transduction.
It was unknown if the effect of these defective Sfrp2 on PLCγ2 is correlated with other abnormal mechanisms in the canonical and/or non-canonical pathways. First, since SFRP2 is not expressed in the hematopoietic cells, especially in splenic B cells compared to BM cells in Sfrp2+/+ mice (Additional file 1), exogenous SFRP2 provided from other tissues may contribute to the calcium signaling in the splenic B cell. Moreover, since β-catenin is rarely detectable as protein levels in these splenic B cells (Additional file 2), exogenous SFRP2 may act on the calcium signaling through non-canonical pathway. However, NFAT1, NFAT2, JNK, and ATF-2, which are considered as members of a cascade in downstream of non-canonical signaling pathway, were found not to play a significant role in the Sfrp2-/- splenic B cells (Figure 4C and D). Taken together, the dysregulation of calcium signaling in the Sfrp2-/- splenic B cells occurs under BCR stimulation and is likely to be correlated with unknown common underlying signal pathway(s) of both BCR and non-canonical signalings.
As previously reported, the expression of SFRP2 was down-regulated by methylation in cancer [14, 15]. Because calcium signaling was reduced by defect of Sfrp2, down-regulation of SFRP2 is assumed to impair the calcium signal transduction in each tissue or cell. However the immune dysfunction was not observed in our SFRP2 deficient mice under the SPF condition, it was reported the association between the methylation of SFRP2 and cancer [14–17]. Although further examination is needed, our results might give us the new insights to understand the functions of SFRP2 under the BCR and calcium signal pathway and the mechanisms of several human diseases.
The defect of Sfrp2 in mice splenic B cells causes the impairment of calcium influx and the activation of PLCγ2 in the BCR signaling pathway. This phenomenon is speculated to be indirectly related to the activations of Wnt pathways.
We thank T. Ichikawa for excellent secretarial assistance and Dr. S. Imashuku for suggestion and reviewing the manuscript. This work was supported by a Grant-in-Aid for Scientific Research (C: 23590368 to TY) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
- Miller JR: The Wnts. Genome Biol. 2002, 3: REVIEWS3001-PubMedPubMed CentralGoogle Scholar
- Huelsken J, Behrens J: The Wnt signalling pathway. J Cell Sci. 2002, 115: 3977-3978. 10.1242/jcs.00089.PubMedView ArticleGoogle Scholar
- Reya T, Clevers H: Wnt signalling in stem cells and cancer. Nature. 2005, 434: 843-850. 10.1038/nature03319.PubMedView ArticleGoogle Scholar
- Suda T, Arai F: Wnt signaling in the niche. Cell. 2008, 132: 729-730. 10.1016/j.cell.2008.02.017.PubMedView ArticleGoogle Scholar
- Rao TP, Kuhl M: An updated overview on Wnt signaling pathways: a prelude for more. Circ Res. 2010, 106: 1798-1806. 10.1161/CIRCRESAHA.110.219840.PubMedView ArticleGoogle Scholar
- Sugimura R, He XC, Venkatraman A, Arai F, Box A, Semerad C, Haug JS, Peng L, Zhong XB, Suda T, Li L: Noncanonical Wnt signaling maintains hematopoietic stem cells in the niche. Cell. 2012, 150: 351-365. 10.1016/j.cell.2012.05.041.PubMedPubMed CentralView ArticleGoogle Scholar
- Sugimura R, Li L: Noncanonical Wnt signaling in vertebrate development, stem cells, and diseases. Birth Defects Res C Embryo Today. 2010, 90: 243-256. 10.1002/bdrc.20195.PubMedView ArticleGoogle Scholar
- Cruciat CM, Niehrs C: Secreted and transmembrane wnt inhibitors and activators. Cold Spring Harb Perspect Biol. 2013, 5: a015081-PubMedPubMed CentralView ArticleGoogle Scholar
- Shirozu M, Tada H, Tashiro K, Nakamura T, Lopez ND, Nazarea M, Hamada T, Sato T, Nakano T, Honjo T: Characterization of novel secreted and membrane proteins isolated by the signal sequence trap method. Genomics. 1996, 37: 273-280. 10.1006/geno.1996.0560.PubMedView ArticleGoogle Scholar
- Satoh W, Matsuyama M, Takemura H, Aizawa S, Shimono A: Sfrp1, Sfrp2, and Sfrp5 regulate the Wnt/beta-catenin and the planar cell polarity pathways during early trunk formation in mouse. Genesis. 2008, 46: 92-103. 10.1002/dvg.20369.PubMedView ArticleGoogle Scholar
- Mii Y, Taira M: Secreted Wnt “inhibitors” are not just inhibitors: regulation of extracellular Wnt by secreted Frizzled-related proteins. Dev Growth Differ. 2011, 53: 911-923. 10.1111/j.1440-169X.2011.01299.x.PubMedView ArticleGoogle Scholar
- Morello R, Bertin TK, Schlaubitz S, Shaw CA, Kakuru S, Munivez E, Hermanns P, Chen Y, Zabel B, Lee B: Brachy-syndactyly caused by loss of Sfrp2 function. J Cell Physiol. 2008, 217: 127-137. 10.1002/jcp.21483.PubMedPubMed CentralView ArticleGoogle Scholar
- Ikegawa M, Han H, Okamoto A, Matsui R, Tanaka M, Omi N, Miyamae M, Toguchida J, Tashiro K: Syndactyly and preaxial synpolydactyly in the single Sfrp2 deleted mutant mice. Dev Dyn. 2008, 237: 2506-2517. 10.1002/dvdy.21655.PubMedView ArticleGoogle Scholar
- Perry AS, O’Hurley G, Raheem OA, Brennan K, Wong S, O’Grady A, Kennedy AM, Marignol L, Murphy TM, Sullivan L, Barrett C, Loftus B, Thornhill J, Hewitt SM, Lawler M, Kay E, Lynch T, Hollywood D: Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer. Int J Cancer. 2013, 132: 1771-1780. 10.1002/ijc.27798.PubMedView ArticleGoogle Scholar
- Cheng YY, Yu J, Wong YP, Man EP, To KF, Jin VX, Li J, Tao Q, Sung JJ, Chan FK, Leung WK: Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer. Br J Cancer. 2007, 97: 895-901.PubMedPubMed CentralGoogle Scholar
- Huang Z, Li L, Wang J: Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci. 2007, 52: 2287-2291. 10.1007/s10620-007-9755-y.PubMedView ArticleGoogle Scholar
- Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E, Tanaka Y, Shibata H, Hashimoto T, Ozaki S, Kido S, Inoue D, Matsumoto T: Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood. 2005, 106: 3160-3165. 10.1182/blood-2004-12-4940.PubMedView ArticleGoogle Scholar
- Fleming HE, Janzen V, Lo Celso C, Guo J, Leahy KM, Kronenberg HM, Scadden DT: Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell. 2008, 2: 274-283. 10.1016/j.stem.2008.01.003.PubMedPubMed CentralView ArticleGoogle Scholar
- Cain CJ, Manilay JO: Hematopoietic stem cell fate decisions are regulated by Wnt antagonists: comparisons and current controversies. Exp Hematol. 2013, 41: 3-16. 10.1016/j.exphem.2012.09.006.PubMedView ArticleGoogle Scholar
- Nakajima H, Ito M, Morikawa Y, Komori T, Fukuchi Y, Shibata F, Okamoto S, Kitamura T: Wnt modulators, SFRP-1, and SFRP-2 are expressed in osteoblasts and differentially regulate hematopoietic stem cells. Biochem Biophys Res Commun. 2009, 390: 65-70. 10.1016/j.bbrc.2009.09.067.PubMedView ArticleGoogle Scholar
- Novak EJ, Rabinovitch PS: Improved sensitivity in flow cytometric intracellular ionized calcium measurement using fluo-3/Fura Red fluorescence ratios. Cytometry. 1994, 17: 135-141. 10.1002/cyto.990170205.PubMedView ArticleGoogle Scholar
- Aragon IV, Barrington RA, Jackowski S, Mori K, Brewer JW: The specialized unfolded protein response of B lymphocytes: ATF6alpha-independent development of antibody-secreting B cells. Mol Immunol. 2012, 51: 347-355. 10.1016/j.molimm.2012.04.001.PubMedPubMed CentralView ArticleGoogle Scholar
- Baba Y, Kurosaki T: Impact of Ca2+ signaling on B cell function. Trends Immunol. 2011, 32: 589-594. 10.1016/j.it.2011.09.004.PubMedView ArticleGoogle Scholar
- Humphries LA, Dangelmaier C, Sommer K, Kipp K, Kato RM, Griffith N, Bakman I, Turk CW, Daniel JL, Rawlings DJ: Tec kinases mediate sustained calcium influx via site-specific tyrosine phosphorylation of the phospholipase Cgamma Src homology 2-Src homology 3 linker. J Biol Chem. 2004, 279: 37651-37661. 10.1074/jbc.M311985200.PubMedView ArticleGoogle Scholar
- Bunney TD, Katan M: PLC regulation: emerging pictures for molecular mechanisms. Trends Biochem Sci. 2011, 36: 88-96. 10.1016/j.tibs.2010.08.003.PubMedView ArticleGoogle Scholar
- Kim YJ, Sekiya F, Poulin B, Bae YS, Rhee SG: Mechanism of B-cell receptor-induced phosphorylation and activation of phospholipase C-gamma2. Mol Cell Biol. 2004, 24: 9986-9999. 10.1128/MCB.24.22.9986-9999.2004.PubMedPubMed CentralView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.